|
1
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Miller KD, Siegel RL, Lin CC, Mariotto AB,
Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer
treatment and survivorship statistics, 2016. CA Cancer J Clin.
66:271–289. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Meng F and Wu G: The rejuvenated scenario
of epithelial-mesenchymal transition (EMT) and cancer metastasis.
Cancer Metastasis Rev. 31:455–467. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang J, Liu D, Feng Z, Mao J, Zhang C, Lu
Y, Li J, Zhang Q, Li Q and Li L: MicroRNA-138 modulates metastasis
and EMT in breast cancer cells by targeting vimentin. Biomed
Pharmacother. 77:135–141. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li C, Wang J, Kong J, Tang J, Wu Y, Xu E,
Zhang H and Lai M: GDF15 promotes EMT and metastasis in colorectal
cancer. Oncotarget. 7:860–872. 2016.PubMed/NCBI
|
|
6
|
Suh SS, Yoo JY, Cui R, Kaur B, Huebner K,
Lee TK, Aqeilan RI and Croce CM: FHIT suppresses
epithelial-mesenchymal transition (EMT) and metastasis in lung
cancer through modulation of microRNAs. PLoS Genet.
10:e10046522014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ombrato L and Malanchi I: The EMT
universe: Space between cancer cell dissemination and metastasis
initiation. Crit Rev Oncog. 19:349–361. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu CH, Tang WC, Sia P, Huang CC, Yang PM,
Wu MH, Lai IL and Lee KH: Berberine inhibits the metastatic ability
of prostate cancer cells by suppressing epithelial-to-mesenchymal
transition (EMT)-associated genes with predictive and prognostic
relevance. Int J Med Sci. 12:63–71. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liang J, Li Y, Daniels G, Sfanos K, De
Marzo A, Wei J, Li X, Chen W, Wang J, Zhong X, et al: LEF1
targeting EMT in prostate cancer invasion is regulated by miR-34a.
Mol Cancer Res. 13:681–688. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kong D, Sethi S, Li Y, Chen W, Sakr WA,
Heath E and Sarkar FH: Androgen receptor splice variants contribute
to prostate cancer aggressiveness through induction of EMT and
expression of stem cell marker genes. Prostate. 75:161–174. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang L, Zhang J, Ma Y, Chen J, Dong B,
Zhao W, Wang X, Zheng Q, Fang F and Yang Y: Testicular orphan
receptor 4 (TR4) is a marker for metastasis and poor prognosis in
non-small cell lung cancer that drives the EMT phenotype. Lung
Cancer. 89:320–328. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ma X, Yan W, Dai Z, Gao X, Ma Y, Xu Q,
Jiang J and Zhang S: Baicalein suppresses metastasis of breast
cancer cells by inhibiting EMT via downregulation of SATB1 and
Wnt/β-catenin pathway. Drug Des Devel Ther. 10:1419–1441. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Huan H, Wen X, Chen X, Wu L, Liu W, Habib
NA, Bie P and Xia F: C/EBPα short-activating RNA suppresses
metastasis of hepatocellular carcinoma through inhibiting
EGFR/β-catenin signaling mediated EMT. PLoS One. 11:e01531172016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Alsuliman A, Colak D, Al-Harazi O, Fitwi
H, Tulbah A, Al-Tweigeri T, Al-Alwan M and Ghebeh H: Bidirectional
crosstalk between PD-L1 expression and epithelial to mesenchymal
transition: Significance in claudin-low breast cancer cells. Mol
Cancer. 14:1492015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang Y, Wang H, Zhao Q, Xia Y, Hu X and
Guo J: PD-L1 induces epithelial-to-mesenchymal transition via
activating SREBP-1c in renal cell carcinoma. Med Oncol. 32:2122015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ock CY, Kim S, Keam B, Kim M, Kim TM, Kim
JH, Jeon YK, Lee JS, Kwon SK, Hah JH, et al: PD-L1 expression is
associated with epithelial-mesenchymal transition in head and neck
squamous cell carcinoma. Oncotarget. 7:15901–15914. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wen W, Liang W, Wu J, Kowolik CM, Buettner
R, Scuto A, Hsieh MY, Hong H, Brown CE, Forman SJ, et al: Targeting
JAK1/STAT3 signaling suppresses tumor progression and metastasis in
a peritoneal model of human ovarian cancer. Mol Cancer Ther.
13:3037–3048. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chang Q, Bournazou E, Sansone P, Berishaj
M, Gao SP, Daly L, Wels J, Theilen T, Granitto S, Zhang X, et al:
The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and
metastasis. Neoplasia. 15:848–862. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sansone P and Bromberg J: Targeting the
interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol.
30:1005–1014. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gao B, Shen X, Kunos G, Meng Q, Goldberg
ID, Rosen EM and Fan S: Constitutive activation of JAK-STAT3
signaling by BRCA1 in human prostate cancer cells. FEBS Lett.
488:179–184. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Teng Y, Ghoshal P, Ngoka L, Mei Y and
Cowell JK: Critical role of the WASF3 gene in JAK2/STAT3 regulation
of cancer cell motility. Carcinogenesis. 34:1994–1999. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tam L, McGlynn LM, Traynor P, Mukherjee R,
Bartlett JM and Edwards J: Expression levels of the JAK/STAT
pathway in the transition from hormone-sensitive to
hormone-refractory prostate cancer. Br J Cancer. 97:378–383. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sun M, Guo X, Qian X, Wang H, Yang C,
Brinkman KL, Serrano-Gonzalez M, Jope RS, Zhou B, Engler DA, et al:
Activation of the ATM-Snail pathway promotes breast cancer
metastasis. J Mol Cell Biol. 4:304–315. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yin S, Wang P, Yang L, Liu Y, Wang Y, Liu
M, Qi Z, Meng J, Shi TY, Yang G and Zang R: Wip1 suppresses ovarian
cancer metastasis through the ATM/AKT/Snail mediated signaling.
Oncotarget. 7:29359–29370. 2016.PubMed/NCBI
|
|
25
|
Kim S, Koh J, Kim MY, Kwon D, Go H, Kim
YA, Jeon YK and Chung DH: PD-L1 expression is associated with
epithelial-to-mesenchymal transition in adenocarcinoma of the lung.
Hum Pathol. 58:7–14. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Doi T, Ishikawa T, Okayama T, Oka K,
Mizushima K, Yasuda T, Sakamoto N, Katada K, Kamada K, Uchiyama K,
et al: The JAK/STAT pathway is involved in the upregulation of
PD-L1 expression in pancreatic cancer cell lines. Oncol Rep.
37:1545–1554. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bellucci R, Martin A, Bommarito D, Wang K,
Hansen SH, Freeman GJ and Ritz J: Interferon-γ-induced activation
of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells
through upregulation of PD-L1 expression. Oncoimmunology.
4:e10088242015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Subhash VV, Tan SH, Yeo MS, Yan FL,
Peethala PC, Liem N, Krishnan V and Yong WP: ATM expression
predicts veliparib and irinotecan sensitivity in gastric cancer by
mediating P53-independent regulation of cell cycle and apoptosis.
Mol Cancer Ther. 15:3087–3096. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Khoronenkova SV and Dianov GL: ATM
prevents DSB formation by coordinating SSB repair and cell cycle
progression. Proc Natl Acad Sci USA. 112:pp. 3997–4002. 2015;
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wojewoda M, Walczak J, Duszyński J and
Szczepanowska J: Selenite activates the ATM kinase-dependent DNA
repair pathway in human osteosarcoma cells with mitochondrial
dysfunction. Biochem Pharmacol. 95:170–176. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
McCabe N, Hanna C, Walker SM, Gonda D, Li
J, Wikstrom K, Savage KI, Butterworth KT, Chen C, Harkin DP, et al:
Mechanistic rationale to target PTEN-deficient tumor cells with
inhibitors of the DNA damage response kinase ATM. Cancer Res.
75:2159–2165. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Singh R, Shankar BS and Sainis KB:
TGF-β1-ROS-ATM-CREB signaling axis in macrophage mediated migration
of human breast cancer MCF7 cells. Cell Signal. 26:1604–1615. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bishop JL, Sio A, Angeles A, Roberts ME,
Azad AA, Chi KN and Zoubeidi A: PD-L1 is highly expressed in
Enzalutamide resistant prostate cancer. Oncotarget. 6:234–242.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Martin AM, Nirschl TR, Nirschl CJ,
Francica BJ, Kochel CM, van Bokhoven A, Meeker AK, Lucia MS, Anders
RA, DeMarzo AM and Drake CG: Paucity of PD-L1 expression in
prostate cancer: Innate and adaptive immune resistance. Prostate
Cancer Prostatic Dis. 18:325–332. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Aalinkeel R, Hu Z, Nair BB, Sykes DE,
Reynolds JL, Mahajan SD and Schwartz SA: Genomic analysis
highlights the role of the JAK-STAT signaling in the
anti-proliferative effects of dietary flavonoid-‘Ashwagandha’ in
prostate cancer cells. Evid Based Complement Alternat Med.
7:177–187. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu RY, Zeng Y, Lei Z, Wang L, Yang H, Liu
Z, Zhao J and Zhang HT: JAK/STAT3 signaling is required for
TGF-β-induced epithelial-mesenchymal transition in lung cancer
cells. Int J Oncol. 44:1643–1651. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Macha MA, Rachagani S, Gupta S, Pai P,
Ponnusamy MP, Batra SK and Jain M: Guggulsterone decreases
proliferation and metastatic behavior of pancreatic cancer cells by
modulating JAK/STAT3 and Src/FAK signaling. Cancer Lett.
341:166–177. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yadav A, Kumar B, Datta J, Teknos TN and
Kumar P: IL-6 promotes head and neck tumor metastasis by inducing
epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signaling
pathway. Mol Cancer Res. 9:1658–1667. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gu L, Talati P, Vogiatzi P, Romero-Weaver
AL, Abdulghani J, Liao Z, Leiby B, Hoang DT, Mirtti T, Alanen K, et
al: Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480
potently inhibits IL-6-induced experimental prostate cancer
metastases formation. Mol Cancer Ther. 13:1246–1258. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xu L, Shen M, Chen X, Zhu R, Yang DR, Tsai
Y, Keng PC, Chen Y and Lee SO: Adipocytes affect
castration-resistant prostate cancer cells to develop the
resistance to cytotoxic action of NK cells with alterations of
PD-L1/NKG2D ligand levels in tumor cells. Prostate. 78:353–364.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang N, Zeng Y, Du W, Zhu J, Shen D, Liu
Z and Huang JA: The EGFR pathway is involved in the regulation of
PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in
EGFR-mutated non-small cell lung cancer. Int J Oncol. 49:1360–1368.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lee DJ, Cha EK, Dubin JM, Beltran H,
Chromecki TF, Fajkovic H, Scherr DS, Tagawa ST and Shariat SF:
Novel therapeutics for the management of castration-resistant
prostate cancer (CRPC). BJU Int. 109:968–985. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chandrasekar T, Yang JC, Gao AC and Evans
CP: Mechanisms of resistance in castration-resistant prostate
cancer (CRPC). Transl Androl Urol. 4:365–380. 2015.PubMed/NCBI
|
|
44
|
Kübler H and Miller K: New therapy
concepts for castration-resistant prostate cancer: Between hormone
manipulation, targeted therapy and chemotherapy. Urologe A.
52(1517–1518): 1520–1521, 1524–1526. 2013.(In German).
|
|
45
|
Qi WX, Fu S, Zhang Q and Guo XM: Efficacy
and toxicity of molecular targeted therapies in combination with
docetaxel for metastatic castration-resistant prostate cancer: A
meta-analysis of phase III randomized controlled trials. J
Chemother. 27:181–187. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Loriot Y, Eymard JC, Patrikidou A, Ileana
E, Massard C, Albiges L, Di Palma M, Escudier B and Fizazi K: Prior
long response to androgen deprivation predicts response to
next-generation androgen receptor axis targeted drugs in castration
resistant prostate cancer. Eur J Cancer. 51:1946–1952. 2015.
View Article : Google Scholar : PubMed/NCBI
|
